Atlas Trials

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Clinical trial NCT03350126 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03350126
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Cancer Colorectal
Start date
2017-12-04
Primary completion
2020-01-10
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.